Get the Stockscreener App
11.56
4.05%
0.45
Turn Therapeutics Inc stock is traded at $11.56, with a volume of 26,707.
It is up +4.05% in the last 24 hours and down -14.12% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
See More
Previous Close:
$11.11
Open:
$10.85
24h Volume:
26,707
Relative Volume:
0.25
Market Cap:
$351.05M
Revenue:
Net Income/Loss:
$-1.77M
P/E Ratio:
-77.74
EPS:
-0.1487
Net Cash Flow:
$-1.46M
1W Performance:
+1.49%
1M Performance:
-14.12%
6M Performance:
+237.03%
1Y Performance:
+126.67%
1-Day Range:
$10.85
$11.88
1-Week Range:
$10.26
$12.00
52-Week Range:
$2.5701
$16.45
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
11.56 | 351.05M | 0 | -1.77M | -1.46M | -0.1487 |
VRTX
Vertex Pharmaceuticals Inc
|
508.54 | 128.90B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.85 | 94.96B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.52 | 82.42B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.03 | 53.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.06 | 42.09B | 5.76B | 514.49M | 1.10B | 4.4813 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics (NASDAQ:TTRX) Raised to Hold at Wall Street Zen - MarketBeat
Turn Therapeutics Inc. (NASDAQ:TTRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Turn Therapeutics GX-03 Shows Positive Interim Phase 2 Data, Cash Runway to Q3 2027 - Minichart
An eczema trial is enrolling about 135 people as Turn Therapeutics (TTRX) awaits results. - Stock Titan
Turn Therapeutics (NASDAQ:TTRX) Cut to Sell at Wall Street Zen - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Lucid Cap Mkts - MarketBeat
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating - Investing.com
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating By Investing.com - Investing.com India
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Turn Therapeutics Inc. (NASDAQ:TTRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Turn Therapeutics' (TTRX) "Sell" Rating Reaffirmed at WBB Securities - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Raised to "Hold" at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - BioSpace
Turn Therapeutics to present at Stifel forum, previewing atopic dermatitis program - TradingView
Turn Therapeutics to Present Atopic Dermatitis Strategy - TipRanks
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - Business Wire
Former CDC Director Dr. Robert R. Redfield Named Chief Scientific Officer at Turn Therapeutics - The Dermatology Digest
Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer - citybiz
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer - BioSpace
Turn Therapeutics Names Robert Redfield Chief Scientific Officer - TipRanks
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer - Dermatology Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TTRX - Finviz
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - kalkinemedia.com
Aldeyra Therapeutics, Inc. (ALDX) Stock Price & News - Syfe
Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX - MarketBeat
Turn (TTRX) Levels: Records a 2.33% Increase to $9.68 in the Current Update; Levels: $9.20 and $10.16 Define the Nearby Reference Levels in the Latest SessionContinuation Pattern Picks - vinanet.vn
Turn (TTRX) Today: Closes 0.84% Lower at $9.46 at the Close; Next Test: the Price Remains Bounded by the Supplied Support and ResistanceAnalyst Upgrade Stocks - vinanet.vn
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordFibonacci Entry Signals - vinanet.vn
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordLow Volatility Picks - siam.in
Turn (TTRX) Results Breakdown: Available Metrics Are Broadly in Line for the Current Session; After Earnings: The Stock Ends Down 2.85% at the CloseGuidance Accuracy Score - vinanet.vn
Turn (TTRX) Close: Ends Lower by 0.20% at $9.80 on the Day; Current Setup: Traders Can Monitor the $9.31-$10.29 Range in Latest TradingWedge Breakout - vinanet.vn
GX-03 Selectively Reduces Key Drivers of Skin Inflammation, Itch - The Dermatology Digest
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model - Dermatology Times
Turn Therapeutics publishes study on GX-03 skin therapy - Investing.com
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com India
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com Canada
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire
Turn Therapeutics Issues 579,664 Shares in Cashless Warrant Exercise - Minichart
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com Nigeria
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance - TipRanks
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com India
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com Canada
Turn Therapeutics Completes Cashless Exercise of GEM Warrant, Issues 579,664 Shares - Kalkine Media
Turn Therapeutics Raises $1.35 Million in Private Placement - Minichart
Turn Therapeutics Secures $1.35 Million Through Private Stock Placement - Kalkine Media
Turn Therapeutics Raises $1.35M Through Private Placement - TipRanks
Turn Therapeutics Inc Stock (TTRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Turn Therapeutics Inc Stock (TTRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOLDEN ARTHUR F | Director |
Nov 24 '25 |
Buy |
3.44 |
9,868 |
33,946 |
60,602 |
| GOLDEN ARTHUR F | Director |
Nov 21 '25 |
Buy |
2.87 |
20,532 |
58,927 |
50,734 |
| Chaudhary Zuraiz | See Remarks |
Nov 21 '25 |
Buy |
3.29 |
1,000 |
3,290 |
10,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 20 '25 |
Buy |
2.61 |
1,450 |
3,784 |
9,000 |
| Chaudhary Zuraiz | See Remarks |
Nov 17 '25 |
Buy |
3.62 |
2,500 |
9,050 |
7,550 |
| Chesed Abraham | Board Observer |
Oct 23 '25 |
Buy |
4.60 |
14,286 |
65,716 |
1,447,268 |
| Chaudhary Zuraiz | See Remarks |
Oct 23 '25 |
Buy |
4.95 |
5,050 |
24,998 |
5,050 |
| GOLDEN ARTHUR F | Director |
Oct 23 '25 |
Buy |
4.95 |
20,202 |
100,000 |
30,202 |
3.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):